Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Facon

Showing results (21-30 of 301) with videos related to

Pageof 31
Sort By:
Seminars in Hematology|April 25, 2009
Frontline treatment in elderly patients with multiple myelomaThierry Facon, Jesus San Miguel, Maria Victoria Mateos, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 22, 2011
Firstline treatment and maintenance in newly diagnosed multiple myeloma patientsMurielle Roussel, Thierry Facon, Philippe Moreau, et al.
British Journal of Haematology|February 13, 2009
Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myelomaNathalie Voorzanger-Rousselot, Delphine Goehrig, Thierry Facon, et al.
European Journal of Internal Medicine|March 15, 2002
Current treatment strategies for multiple myelomaBernard Grosbois, Olivier Decaux, Isabelle Azais, et al.
The Lancet. Oncology|February 5, 2026
Daratumumab-lenalidomide and the immunosuppressive budget in myeloma - Authors' replySalomon Manier, Jérôme Lambert, Cyrille Hulin, et al.
Best Practice & Research. Clinical Haematology|July 20, 2005
Stem-cell transplantation in multiple myelomaJean-Luc Harousseau, Philippe Moreau, Michel Attal, et al.
The New England Journal of Medicine|May 30, 2003
A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemiaCatherine Roche-Lestienne, Jean-Luc Laï, Stéphane Darré, et al.
Haematologica|November 10, 2004
Evaluation of gemcitabine in relapsed or refractory multiple myelomaXavier Leleu, Jacques Troncy, Fadela Bouafia, et al.
Clinical Trials (London, England)|July 4, 2013
Modeling of experts' divergent prior beliefs for a sequential phase III clinical trialMarion Moatti, Sarah Zohar, Thierry Facon, et al.
Expert Review of Anticancer Therapy|June 23, 2018
Maintenance and continuous therapy for multiple myelomaPaul G Richardson, Jacob Laubach, Sara Gandolfi, et al.
Pageof 31

Showing results (21-30 of 301) with videos related to

Sort By:
Pageof 31
Seminars in Hematology|April 25, 2009
Frontline treatment in elderly patients with multiple myelomaThierry Facon, Jesus San Miguel, Maria Victoria Mateos, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 22, 2011
Firstline treatment and maintenance in newly diagnosed multiple myeloma patientsMurielle Roussel, Thierry Facon, Philippe Moreau, et al.
British Journal of Haematology|February 13, 2009
Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myelomaNathalie Voorzanger-Rousselot, Delphine Goehrig, Thierry Facon, et al.
European Journal of Internal Medicine|March 15, 2002
Current treatment strategies for multiple myelomaBernard Grosbois, Olivier Decaux, Isabelle Azais, et al.
The Lancet. Oncology|February 5, 2026
Daratumumab-lenalidomide and the immunosuppressive budget in myeloma - Authors' replySalomon Manier, Jérôme Lambert, Cyrille Hulin, et al.
Best Practice & Research. Clinical Haematology|July 20, 2005
Stem-cell transplantation in multiple myelomaJean-Luc Harousseau, Philippe Moreau, Michel Attal, et al.
The New England Journal of Medicine|May 30, 2003
A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemiaCatherine Roche-Lestienne, Jean-Luc Laï, Stéphane Darré, et al.
Haematologica|November 10, 2004
Evaluation of gemcitabine in relapsed or refractory multiple myelomaXavier Leleu, Jacques Troncy, Fadela Bouafia, et al.
Clinical Trials (London, England)|July 4, 2013
Modeling of experts' divergent prior beliefs for a sequential phase III clinical trialMarion Moatti, Sarah Zohar, Thierry Facon, et al.
Expert Review of Anticancer Therapy|June 23, 2018
Maintenance and continuous therapy for multiple myelomaPaul G Richardson, Jacob Laubach, Sara Gandolfi, et al.
Pageof 31